Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
6.22
USD
|
+2.13%
|
|
-2.51%
|
+23.17%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
274.8
|
383.9
|
184.7
|
608.4
|
601.6
|
761.7
|
-
|
-
|
Enterprise Value (EV)
1 |
127.7
|
199.4
|
34.17
|
519.9
|
401.3
|
595.4
|
649.1
|
761.7
|
P/E ratio
|
-1.4
x
|
-2.06
x
|
-1.33
x
|
-3.41
x
|
-9.35
x
|
-7.04
x
|
-6.59
x
|
-8.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17.2
x
|
19.1
x
|
4.51
x
|
167
x
|
5.31
x
|
11.2
x
|
15
x
|
8.59
x
|
EV / Revenue
|
7.99
x
|
9.93
x
|
0.83
x
|
142
x
|
3.54
x
|
8.78
x
|
12.7
x
|
8.59
x
|
EV / EBITDA
|
-641,191
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.66
x
|
-1.7
x
|
-0.38
x
|
-4.03
x
|
-19.5
x
|
-4.54
x
|
-4.82
x
|
-4.03
x
|
FCF Yield
|
-151%
|
-58.9%
|
-262%
|
-24.8%
|
-5.12%
|
-22%
|
-20.7%
|
-24.8%
|
Price to Book
|
3.79
x
|
4.64
x
|
4.65
x
|
-13.5
x
|
15.2
x
|
13.5
x
|
-27
x
|
-
|
Nbr of stocks (in thousands)
|
34,290
|
48,778
|
58,833
|
86,910
|
119,138
|
122,460
|
-
|
-
|
Reference price
2 |
8.015
|
7.870
|
3.140
|
7.000
|
5.050
|
6.220
|
6.220
|
6.220
|
Announcement Date
|
3/2/20
|
3/4/21
|
3/3/22
|
3/22/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
15.98
|
20.08
|
40.96
|
3.649
|
113.3
|
67.81
|
50.93
|
88.67
|
EBITDA
|
-199.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-208.3
|
-153.4
|
-127
|
-162.7
|
-68
|
-139.1
|
-140.6
|
-128.1
|
Operating Margin
|
-1,303.37%
|
-763.94%
|
-310.07%
|
-4,459.3%
|
-60.01%
|
-205.17%
|
-276.01%
|
-144.48%
|
Earnings before Tax (EBT)
1 |
-193.6
|
-150.8
|
-122.4
|
-161.1
|
-58.19
|
-129.6
|
-134
|
-121.6
|
Net income
1 |
-193.6
|
-149.9
|
-122.2
|
-161.8
|
-57.51
|
-118.9
|
-138.6
|
-118.8
|
Net margin
|
-1,211.52%
|
-746.68%
|
-298.42%
|
-4,434.72%
|
-50.76%
|
-175.32%
|
-272.12%
|
-134%
|
EPS
2 |
-5.720
|
-3.820
|
-2.360
|
-2.050
|
-0.5400
|
-0.8840
|
-0.9440
|
-0.7333
|
Free Cash Flow
1 |
-192.1
|
-117.4
|
-89.55
|
-129.1
|
-20.55
|
-131.1
|
-134.6
|
-189.2
|
FCF margin
|
-1,202.21%
|
-584.6%
|
-218.61%
|
-3,539.11%
|
-18.13%
|
-193.33%
|
-264.36%
|
-213.32%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/4/21
|
3/3/22
|
3/22/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.765
|
1.75
|
0.375
|
0.285
|
1.239
|
12.93
|
22.11
|
49.21
|
29.06
|
12.54
|
2
|
2
|
33
|
10
|
14.17
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-36.11
|
-38.09
|
-42.16
|
-38.9
|
-43.56
|
-30.28
|
-23.47
|
4.444
|
-18.68
|
-34.46
|
-47
|
-46
|
-18
|
-40.31
|
-36.83
|
Operating Margin
|
-2,045.89%
|
-2,176.8%
|
-11,243.73%
|
-13,648.77%
|
-3,515.98%
|
-234.24%
|
-106.18%
|
9.03%
|
-64.3%
|
-274.83%
|
-2,350%
|
-2,300%
|
-54.55%
|
-403.11%
|
-259.97%
|
Earnings before Tax (EBT)
1 |
-34.99
|
-37.81
|
-41.3
|
-39
|
-43.03
|
-27.4
|
-21.1
|
6.575
|
-16.26
|
-31.56
|
-46
|
-45
|
-18
|
-38.44
|
-34.96
|
Net income
1 |
-34.78
|
-37.81
|
-41.3
|
-39
|
-43.71
|
-27.4
|
-21.1
|
6.995
|
-16.26
|
-31.56
|
-24.14
|
-31.25
|
-32.26
|
-38.44
|
-34.96
|
Net margin
|
-1,970.82%
|
-2,160.8%
|
-11,012.27%
|
-13,685.61%
|
-3,527.76%
|
-211.97%
|
-95.47%
|
14.21%
|
-55.95%
|
-251.7%
|
-1,206.87%
|
-1,562.6%
|
-97.76%
|
-384.44%
|
-246.8%
|
EPS
2 |
-0.6100
|
-0.6200
|
-0.6200
|
-0.4200
|
-0.4500
|
-0.2700
|
-0.2000
|
0.0700
|
-0.1500
|
-0.2400
|
-0.1800
|
-0.2300
|
-0.2340
|
-0.2733
|
-0.2233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/22/23
|
5/3/23
|
8/3/23
|
11/9/23
|
3/6/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
147
|
184
|
151
|
88.5
|
200
|
166
|
113
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-192
|
-117
|
-89.6
|
-129
|
-20.5
|
-131
|
-135
|
-189
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.110
|
1.700
|
0.6700
|
-0.5200
|
0.3300
|
0.4600
|
-0.2300
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
3.92
|
1.39
|
0.56
|
1.36
|
1.12
|
1.02
|
1.3
|
1.42
|
Capex / Sales
|
24.51%
|
6.91%
|
1.37%
|
37.3%
|
0.98%
|
1.5%
|
2.54%
|
1.6%
|
Announcement Date
|
3/2/20
|
3/4/21
|
3/3/22
|
3/22/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
6.22
USD Average target price
12.86
USD Spread / Average Target +106.71% Consensus |
1st Jan change
|
Capi.
|
---|
| +23.17% | 762M | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.66% | 22.1B | | -9.05% | 18.34B | | -41.70% | 16.59B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|